Company intelligence / Profile preview

Waterstone Pharmaceuticals

Wuhan, Hubei, Chinawaterstonepharma.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Waterstone has multiple products in development, including WS016 for hyperkalemia in Phase 2 clinical trials and WS012 which completed Phase 1 trials. The company has 40+ marketed drugs in China and several candidates in Phase II/III clinical trials with cFDA.

Therapeutic areas: GastroenterologyMetabolic DisordersNephrology
Modalities: Small MoleculesAPIs (Active Pharmaceutical Ingredients)
Industry: Biotech

Drug pipeline

5 assets

WS016

4 more assets in the full pipeline.

Partnerships

Chime Biologics (strategic partnership for ADC industry announced November 12, 2024)

Beyond the preview

Go deeper on Waterstone Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Waterstone Pharmaceuticals.